» Articles » PMID: 34711689

Biphasic Regulation of Mitogen-Activated Protein Kinase Phosphatase 3 in Hypoxic Colon Cancer Cells

Overview
Journal Mol Cells
Publisher Elsevier
Date 2021 Oct 29
PMID 34711689
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia, or low oxygen tension, is a hallmark of the tumor microenvironment. The hypoxia-inducible factor-1α (HIF-1α) subunit plays a critical role in the adaptive cellular response of hypoxic tumor cells to low oxygen tension by activating gene-expression programs that control cancer cell metabolism, angiogenesis, and therapy resistance. Phosphorylation is involved in the stabilization and regulation of HIF-1α transcriptional activity. HIF-1α is activated by several factors, including the mitogen-activated protein kinase (MAPK) superfamily. MAPK phosphatase 3 (MKP-3) is a cytoplasmic dual-specificity phosphatase specific for extracellular signal-regulated kinase 1/2 (Erk1/2). Recent evidence indicates that hypoxia increases the endogenous levels of both MKP-3 mRNA and protein. However, its role in the response of cells to hypoxia is poorly understood. Herein, we demonstrated that small-interfering RNA (siRNA)-mediated knockdown of MKP-3 enhanced HIF-1α (not HIF-2α) levels. Conversely, MKP-3 overexpression suppressed HIF-1α (not HIF-2α) levels, as well as the expression levels of hypoxia-responsive genes (, , , and ), in hypoxic colon cancer cells. These findings indicated that MKP-3, induced by HIF-1α in hypoxia, negatively regulates HIF-1α protein levels and hypoxia-responsive genes. However, we also found that long-term hypoxia (12 h) induced proteasomal degradation of MKP-3 in a lactic acid-dependent manner. Taken together, MKP-3 expression is modulated by the hypoxic conditions prevailing in colon cancer, and plays a role in cellular adaptation to tumor hypoxia and tumor progression. Thus, MKP-3 may serve as a potential therapeutic target for colon cancer treatment.

Citing Articles

Roles and therapeutic potential of the SLC family in prostate cancer-literature review.

Fu Y, Chen J, Zhu X, Ding M, Wang H, Fu S BMC Urol. 2025; 25(1):32.

PMID: 39966814 PMC: 11837367. DOI: 10.1186/s12894-025-01714-w.


Scoparone attenuates PD-L1 expression in human breast cancer cells by MKP-3 upregulation.

Kim S, Kim C, Kim H Anim Cells Syst (Seoul). 2024; 28(1):55-65.

PMID: 38348341 PMC: 10860470. DOI: 10.1080/19768354.2024.2315950.


DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions.

Zhang C, Wu L, Li Z, Zhang M, Wu J, Du F Int J Oncol. 2022; 60(4).

PMID: 35244188 PMC: 8923653. DOI: 10.3892/ijo.2022.5335.

References
1.
Warmka J, Mauro L, Wattenberg E . Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras. J Biol Chem. 2004; 279(32):33085-92. DOI: 10.1074/jbc.M403120200. View

2.
Walenta S, Mueller-Klieser W . Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol. 2004; 14(3):267-74. DOI: 10.1016/j.semradonc.2004.04.004. View

3.
Jurek A, Amagasaki K, Gembarska A, Heldin C, Lennartsson J . Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation. J Biol Chem. 2008; 284(7):4626-34. DOI: 10.1074/jbc.M808490200. View

4.
Zhu M, Tong J, Xu Q, Nie F, Xu X, Xiao S . Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer. PLoS One. 2012; 7(8):e41763. PMC: 3411563. DOI: 10.1371/journal.pone.0041763. View

5.
Chang L, Karin M . Mammalian MAP kinase signalling cascades. Nature. 2001; 410(6824):37-40. DOI: 10.1038/35065000. View